Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.

Authors

John N Allan
Javier Pinilla-Ibarz
Douglas E Gladstone
Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
Jeff P Sharman
William G Wierda
Michael Y Choi
Susan M O'Brien
Mazyar Shadman
Matthew S Davids
John M Pagel, SWEDISH CANCER INSTITUTE.Follow
Habte A Yimer
Renee Ward
Gary Acton
Pietro Taverna
Daniel L Combs
Judith A Fox
Richard R Furman
Jennifer R Brown

Document Type

Article

Publication Date

12-23-2021

Publication Title

Haematologica

Keywords

seattle; swedish cancer; washington

Abstract

Not available.

Clinical Institute

Cancer

Department

Oncology

Recommended Citation

Allan, John N; Pinilla-Ibarz, Javier; Gladstone, Douglas E; Patel, Krish; Sharman, Jeff P; Wierda, William G; Choi, Michael Y; O'Brien, Susan M; Shadman, Mazyar; Davids, Matthew S; Pagel, John M; Yimer, Habte A; Ward, Renee; Acton, Gary; Taverna, Pietro; Combs, Daniel L; Fox, Judith A; Furman, Richard R; and Brown, Jennifer R, "Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies." (2021). Articles, Abstracts, and Reports. 5499.
https://digitalcommons.providence.org/publications/5499